Evaluating the Clinical Meaning of Dermatology Life Quality Index Scores Between Different Phenotypes of Atopic Dermatitis in Patients Before and After Biologic Therapy With Dupilumab

background and objective: atopic dermatitis (AD) is the most prevalent inflammatory skin disorder resulting in an intense impact on patients quality of life. the aim of this study is to evaluate the clinical meaning of the DLQI scores documented between different phenotypes of AD patients under biologic therapy with dupilumab.method: we conducted a retrospective analysis of 209 patients with AD treated with dupilumab for 2 years. these patients were categorized into different clinical phenotypes. severity of the disease was assessed by using the eczema area and severity Index (EASI), numerical scale rating (NRS) for sleep (NRS sleep), pruritus (NRS pruritus) and dermatology life quality Index (DLQI) at baseline and subsequently at 4,12 and 24 months. results: our results show that the higher DLQI scores (mean: 18.6, range:9-30) achieved at T0 are associated with a prurigo nodularis AD pattern, while after 24 months (T3) of therapy with dupilumab, the worst quality of life index results were reported in Flexural and Head-Neck combined clinical phenotypes. conclusions: quality of life is probably what matters most as an overall endpoint in AD. assessing the clinical meaning of DLQI scores across different AD phenotypes could be a further aid when considering decision making factors in patient management.